Department of Radiation Oncology, Regional Cancer Centre, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Department of General Surgery, Rajindra Medical College, Patiala, India.
Asia Pac J Clin Oncol. 2024 Oct;20(5):565-571. doi: 10.1111/ajco.13945. Epub 2023 Mar 23.
In this study, we compared outcomes in young and very young patients with breast cancer (BC).
Between January 1990 to December 2010, 414 young women (age ≤35 years) with BC were registered in the radiotherapy (RT) outpatient department. Patients were divided into young (31-35 years) and very young (18-30 years). They were compared for clinical, pathological characteristics, and treatment-related factors such as RT and systemic therapy. Outcomes compared between the two groups were locoregional recurrence rate (LRR), local recurrence-free survival (LRFS), disease-free survival (DFS), overall survival (OS), and toxicities. LRFS, DFS, and OS were estimated using the Kaplan-Meier method.
Out of 414 patients, 138 and 276 were very young and young, respectively. Clinical, pathological, and treatment characteristics were balanced between the two groups except for more patients in the young group who had pN3 disease and received hormonal therapy; 41 (15%) versus seven (5%) and 171 (62%) versus 62 (45%) in the very young group, respectively. Median follow-up was 84 months (range 12-363 months). LR was seen in 16 (11.6%) and 25 (9%) patients in the very young and young groups, respectively (p = 0.28). The hazard ratios for LR, disease recurrence, and death in the very young group relative to the young group were 1.11 (p = 0.25), 1.0 (p = 1.0), and 1.05 (p = 0.79), respectively. Estimated 10-year LRFS, DFS and OS were 80% versus 86%, 63% versus 61%, and 66% versus 64% in the very young and young groups, respectively. Lymphedema, cardiac toxicity, and second malignancy developed in seven (5%) versus 23 (8%), one (1%) versus three (1%), and seven (5%) versus 18 (7%) patients in the very young and young groups, respectively.
In very young and young patients with BC, there was no significant difference in LRR, LRFS, DFS, or OS. Toxicities were also comparable between the two groups.
本研究旨在比较年轻和极年轻乳腺癌患者的治疗结果。
1990 年 1 月至 2010 年 12 月期间，共有 414 名年龄≤35 岁的年轻女性患者在我院放疗门诊登记，将患者分为年轻组（31-35 岁）和极年轻组（18-30 岁）。对两组患者的临床病理特征及放疗和全身治疗等治疗相关因素进行比较。比较两组患者的局部区域复发率（LRR）、局部无复发生存率（LRFS）、无病生存率（DFS）、总生存率（OS）及毒性反应。采用 Kaplan-Meier 法估计 LRFS、DFS 和 OS。
414 例患者中，极年轻组和年轻组分别为 138 例和 276 例。两组患者的临床、病理和治疗特征基本均衡，仅年轻组 pN3 疾病患者更多，且接受激素治疗的患者也更多，分别为 41 例（15%）、7 例（5%）和 171 例（62%）、62 例（45%）。中位随访时间为 84 个月（范围 12-363 个月）。极年轻组和年轻组的 LRR 分别为 16 例（11.6%）和 25 例（9%）（p=0.28）。极年轻组患者的 LR、疾病复发和死亡风险比年轻组分别为 1.11（p=0.25）、1.0（p=1.0）和 1.05（p=0.79）。极年轻组和年轻组患者的 10 年 LRFS、DFS 和 OS 估计值分别为 80%对 86%、63%对 61%和 66%对 64%。极年轻组和年轻组的淋巴水肿、心脏毒性和第二原发恶性肿瘤发生率分别为 7 例（5%）、23 例（8%）、1 例（1%）、3 例（1%）和 7 例（5%）、18 例（7%）。
在年轻和极年轻的乳腺癌患者中，LRR、LRFS、DFS 和 OS 无显著差异。两组患者的毒性反应也相似。
